The company said it also led to a 67% reduction in headache severity at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Let's have a look at the gap up and gap down stocks in today's session.

Quantum BioPharma Ltd. Dual Lists on Upstream's Global Securities Trading App

Trading to become available January 14th under 'QNTM'

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Shares of Quantum BioPharma Ltd. (NASDAQQNTM) are soaring more than 70% on Tuesday after the company announced positive clinical trial results for its dietary supplement, unbuzzd, which accelerates the reduction of blood alcohol concentration.

Quantum BioPharma (NASDAQQNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing heart rate and blood pressure. Participants also reported reduced mental fatigue and hangover symptoms without adverse side effects. Quantum BioPharma CEO Zeeshan Saeed highlighted unbuzzd as a breakthrough in promoting safe and responsible alcohol consumption.

Quantum BioPharma Ltd (NASDAQQNTM) shares are rising Tuesday after the company announced positive clinical trial results for its unbuzzd dietary supplement.

Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover

Quantum BioPharma (NASDAQQNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd(TM), a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

Awards in favour of Quantum BioPharma Total Approximately $3 Million

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency.

TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that the safety review committee recommends commencing dosing of the second cohort in its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." The safety review committee made this recommendation after reviewing safety and pharmacokinetic data from participants in the first cohort.

TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (Nasdaq:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the extent determined by the courts. As a result, prominent legal teams have been assembled to pursue the recovery of all losses and damages impacting our Company. The law firms have agreed to be compensated without cost to the Company but solely on a contingency basis, meaning that the Company will not be billed for legal costs in this matter. The Company itself is seeking damages of more than US$700M we believe it has suffered. The shareholders can find updated information about the case on the Quantum vs Banks page of our website which will be updated periodically.

TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that sentinel dosing has started for its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."

To assist enquiries the copy of the complaint can be viewed by clicking the following link: Quantum Bio Pharma Complaint

Quantum BioPharma Ltd. Alleges Market Manipulation, Files Lawsuit, unbuzzed Continues To Gain Traction

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders

As the health and wellness sector gains momentum, consumers are increasingly seeking products that can aid recovery from the effects of alcohol. Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM), a company focused on developing innovative health solutions, is well-positioned to meet this demand with its groundbreaking product designed to support the body in metabolizing alcohol.